Patients Are Waiting
Patients are our purpose and north star.
We act with urgency because lives depend on it.
We are a clinical-stage immunology company, dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in anti FcRn technology, we are developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases.
Immunovant’s two investigational products, IMVT-1402 and batoclimab, are novel, fully human, monoclonal antibodies that target FcRn and may reduce harmful immunoglobulin G (IgG) autoantibodies, which are common causes of autoimmune disease. We believe that both product candidates have the potential to address a variety of IgG-mediated autoimmune diseases as subcutaneous injections with dosing that may be tailored, based on disease stage and severity.
Patients are our purpose and north star.
We act with urgency because lives depend on it.
Unity, collaboration, and trust in action.
We win together - no silos, no egos.
Excellence starts with - and grows through - our people.
We set a high bar and invest in those who clear it.
Integrity and accountability in everything we do.
We own outcomes, not just tasks.
Clear goals. Merit-based recognition.
We focus on impact and celebrate results.
Innovation drives progress.
We challenge assumptions, think beyond the obvious, and build better solutions.
Patients are our purpose and north star.
We act with urgency because lives depend on it.
Unity, collaboration, and trust in action.
We win together - no silos, no egos.
Excellence starts with - and grows through - our people.
We set a high bar and invest in those who clear it.
Integrity and accountability in everything we do.
We own outcomes, not just tasks.
Clear goals. Merit-based recognition.
We focus on impact and celebrate results.
Innovation drives progress.
We challenge assumptions, think beyond the obvious, and build better solutions.